g1t38
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02821624)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- g1t38
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03455829 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2018 | G1 Therapeutics, Inc. |
| NCT02983071 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | G1 Therapeutics, Inc. |
| NCT02821624 | Phase 1 | May 1, 2016 | G1 Therapeutics, Inc., Pharmaceutical Research Associates, Inc. (PRA) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| G1 Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2016 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1